Mycobacterium tuberculosis causes tuberculosis (TB) which in only few patients have advanced from latent TB to drug-sensitive tuberculosis (DSTB) or drugresistant tuberculosis, indicating effective immune mechanisms. One of such is nitric oxide (NO) whose role is not fully elucidated in its defense against human TB.
Background
Mycobacterium tuberculosis causes tuberculosis (TB) which in only few patients have advanced from latent TB to drug-sensitive tuberculosis (DSTB) or drugresistant tuberculosis, indicating effective immune mechanisms. One of such is nitric oxide (NO) whose role is not fully elucidated in its defense against human TB.
Patients and methods
This study determined the levels of NO in the sputum, mononuclear cell lysate, and plasma of 60 DSTB patients, 60 multidrug-resistant tuberculosis (MDRTB) patients before and during chemotherapy compared with 50 apparently healthy participants. Result Plasma NO level was significantly reduced in MDRTB patients compared with the control and DSTB (P<0.05) but the plasma level of NO in DSTB patients compared with the control was similar. The levels of lysate NO were significantly reduced in DSTB patients and MDRTB patients compared with control (P<0.05). Sputum NO levels were significantly elevated in DSTB patients (P<0.05) and MDRTB patients (P<0.05) compared with the control. In DSTB patients, there were no significant differences in NO levels in the plasma or lysate during the 6 months chemotherapy compared with the NO levels before chemotherapy. In MDRTB patients, plasma NO were significantly raised at 2 and 4 months of anti-TB chemotherapy compared with the levels before chemotherapy. Lysate NO levels were significantly raised whereas sputum NO were significantly reduced at 4 and 6 months of anti-TB chemotherapy compared with the levels before start of chemotherapy. Also lysate NO was significantly raised at 4 months of anti-TB chemotherapy compared with at 2 months of anti-TB chemotherapy, whereas sputum NO was significantly reduced at 6 months of anti-TB chemotherapy compared with at 2 months of anti-TB chemotherapy.
Conclusion
Taken together, the study shows that NO plays a vital role in human innate immune Introduction Tuberculosis (TB) remains a major worldwide health problem worldwide especially in developing countries [1] . Many factors from the host, environment, Mycobacterium tuberculosis bacteria, and coinfections have been attributed to ineffective control of TB or rapid progression of latent TB to drug-sensitive tuberculosis (DSTB) or drug-resistant tuberculosis [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Suggested attempts to control or prevent TB-associated mortality and mortality include development of new drugs and vaccines, complete understanding of host M. tuberculosis interaction, more accurate and rapid diagnostic tools as well as research on therapeutic strategies that target the immune system [3, 4, 8, 9] . To provide additional information on immune responses to M. tuberculosis infection, this study focused primarily on the role of nitric oxide (NO) in the innate immune defense against M. tuberculosis.
Epidemiological and experimental observations indicate effective innate immune mechanisms against M. tuberculosis which include interferon-gamma, tumor necrosis factor-alpha, and NO interaction among others [12, 13] . NO is mainly generated by nitric oxide synthases (NOS) which catalyze the oxidation of L-arginine to NO and L-citrulline in a NADPH-dependent and O 2 -dependent manner [14] but in the absence of L-arginine, NOS acts as a superoxide generator [15] . In murine models, it has been shown that NO is essential for host defense against M. tuberculosis, but the role of NO has not been fully established in humans [16, 17] . Alveolar macrophages and peripheral monocytes from TB patients express higher levels of inducible nitric oxide synthase (iNOS) than controls [18] [19] [20] . Levels of nitrite, interleukin-1 beta, and tumor necrosis factor-alpha were also higher from alveolar macrophages of TB patients compared with normal participants, and it was reported that high production of nitrite by alveolar macrophages was associated with increased resolution of TB [20, 21] .
Despite confirmed anti-M. tuberculosis activity of NO, M. tuberculosis inhibits transportation of iNOS to the phagosome [22] as well as inhibits recruitment of H + -ATPase and acidification of the phagosome [23] . However, it was reported that pathogenic mycobacteria are inherently more resistant than nonpathogenic to reactive nitrogen species (RNS) [24, 25] . Thus, there is need to determine the levels of NO in DSTB patients and multidrug-resistant tuberculosis (MDRTB) before and during chemotherapy. Also, to find out the levels of NO in local environments (polymorphonuclear cells and sputum) of M. tuberculosis and in systemic circulation (plasma) of TB patients. To the knowledge of the author, this is the first study analyzing NO levels on mononuclear cell lysate, plasma, and sputum of TB patients.
Patients and methods Participants
A total of 160 participants were enrolled for this study after obtaining institutional ethical approval and informed consent for the participants. This comprised 50 MDRTB patients, 60 DSTB patients, and 50 non-TB apparently healthy controls. MDRTB patients had been previously diagnosed as being infected with isoniazid-and rifampicin-resistant strains of M. tuberculosis using clinical history, chest radiography, and GENE Xpert. These patients were admitted into the MDRTB Centre, University College Hospital, Ibadan, Nigeria for anti-TB treatment. DSTB patients were recruited from the Medicine Outpatient Clinic, University College Hospital, Ibadan, Nigeria by a Consultant Chest Physician after confirmation with microbiological test (sputum smear microscopy), chest radiography, and clinical history.
Sputum preparation
The mouth was rinsed with water to remove particles in the mouth and early morning sputum samples were collected into sterile bottles to avoid contamination. In the laboratory, the sputum samples were diluted in phosphate-buffer saline at a ratio 1 : 1 dilution factor. The mixture was centrifuged and the clear supernatant was collected and stored for analysis at −20°C.
Mononuclear cell lysate preparation and plasma separation
Three milliliters of blood was drawn from the antecubital vein of each participant into a lithium heparin tube and mixed with 3 ml of phosphatebuffered saline. Lymphoprep (6 ml) was carefully layered on it and was at 600 g for 15 min to obtain separately the mononuclear cells and plasma above the mixture of polymorphonuclear cells and red blood cells. Mononuclear cells obtained were washed, resuspended in Ringer's solution, counted, and adjusted to 0.5 ×10 6 cells/ml. Mononuclear cell lysate was obtained by the freeze-thaw method as described [26] . Cell suspension was frozen for 15 min at −20°C and thawed at 4°C for 30 min. This procedure of freezing (−20°C, 15 min) and thawing (4°C, 30 min) was repeated to make three cycles. Microscopic examination confirmed complete disruption of mononuclear cells. Lysate was stored at −20°C until analysis.
Nitric oxide analysis
Plasma NO was estimated using Griess Reagent as previously described [27] . It is based on a chemical reaction which uses sulfanilamide and N-1napthyethylenediamine dihydrochloride under acidic (phosphoric acid) conditions. Nitrite forms a colored chromophore with the reagent, with an absorbance maximum at 540 nm wavelength, which is measured with an enzyme-linked immunosorbent assay microplate reader. The production of nitrite was quantified by comparing the result with absorbances of standard solutions of sodium nitrite.
Statistical analysis
Student's t test was used to compare the mean values. A P value less than or equal to 0.05 was considered as statistically significant. In DSTB patients, there were no significant differences in NO levels during the 6 months of chemotherapy compared with NO levels before start of chemotherapy (Table 2 ). In MDRTB patients, plasma NO were significantly raised at 2 and 4 months of anti-TB chemotherapy compared with the levels before start of chemotherapy. Lysate NO levels were significantly raised whereas sputum NO were significantly reduced at 4 and 6 months of anti-TB chemotherapy compared with the levels before start of chemotherapy. Also lysate NO was significantly raised at 4 months of anti-TB chemotherapy compared with at 2 months of anti-TB chemotherapy, whereas sputum NO was significantly reduced at 6 months of anti-TB chemotherapy compared with at 2 months of anti-TB chemotherapy ( Table 3 ).
Results

As shown in (
Discussion
NO produced by activated macrophages from Larginine, through the activity of iNOS is found to be important in the defense against M. tuberculosis infection [12] [13] [14] , especially in animals and macrophages in-vitro studies [14] [15] [16] [17] , although the relative importance of NO in defense against human TB is controversial [16, 17] .
M. tuberculosis enters the body almost exclusively by the airway and is usually located in the lungs, causing pulmonary TB. M. tuberculosis can spread through the blood and it produces extrapulmonary tuberculosis, with involvement of the lymph nodes, pleura, genitourinary system, meninges, and peritoneum [28, 29] . Pulmonary TB is the main clinical form of the disease and is classified into primary and postprimary (or reactivation). In the primary foci infiltration of lymphocytes, monocytes, and macrophages occur [29, 30] . Macrophages engulf the bacilli and complex interaction of other immune cells, cytokines, and other proteins start [30] [31] [32] . This transverse ability of M. tuberculosis from sputum to blood provides the basis for the use of sputum, mononuclear cell lysate, and plasma as samples for the analysis of NO in TB patients in this study. Also, the intricate complexity of immune cells and regulating proteins during M. tuberculosis and host interaction stimulate the search for more effective treatments, diagnosis, and eradication of TB, which is one of the leading causes of mortality and morbidity worldwide.
Since previous studies have shown that susceptibility of mycobacteria to RNS can be strain dependent [24, 25] , this study determined the levels of NO in DSTB and MDRTB patients before and during chemotherapy. Most previous studies were mainly on the concentrations of urinary and exhaled NO in TB patients [18, 19] . This is the first of such study using sputum, mononuclear lysate, and plasma. The major contributions of this study are that NO is associated with resistance of M. tuberculosis and anti-TB chemotherapy and that local environment (mononuclear cell lysate) of M. tuberculosis showed more relation with M. tuberculosis infection than plasma.
Plasma and lysate NO levels were significantly reduced in and DSTB and MDRTB patients compared with the control. This might be an indication of consumption of NO in an attempt to control M. tuberculosis infection or suppression of host's NO production by M. tuberculosis. In this way, the bacteria escape the cells, evade the host defenses, and spread to uninfected cells. It was reported that M. tuberculosis evolved immune escape mechanisms to survive within macrophages. Survival strategies of M. tuberculosis against the host immune response include inhibition of phagosomal acidification, bacterial proteases, modification of the bacterial cell wall to resist antimicrobial peptides, and inhibition of the production of reactive oxygen species (ROS) and RNS [18] [19] [20] [21] [22] [23] . M. tuberculosis carries scavenger functions against ROS and RNS in order not to face decreased growth rate, due to enzyme damage or nutrient depletion [14] [15] [16] [17] [18] , thus explaining the decreased levels of NO in TB patients reported in the study.
The mechanism(s) by which M. tuberculosis suppresses NO production varies. The proline-proline-glutamate protein family are abundant in pathogenic mycobacteria. These proline-proline-glutamate proteins act as repressive transcription factors in the macrophage nucleus to suppress NOS 2 expression and thereby reduce the release of the anti-mycobacterial NO molecule [33] .
The plasma level of NO was found to be reduced in MDRTB patients compared with DSTB, suggesting a mechanism for differences in pathogenicity of M. tuberculosis bacteria in MDRTB compared with DRTB patients. As previously reported, certain strains of M. tuberculosis can resist RNS generated in vitro. It was shown that pathogenic mycobacteria are inherently more resistant than nonpathogenic to RNS and have several antioxidant systems and clinical strains vary in susceptibility to NO produced by acidified nitrite [23] [24] [25] . The catalase peroxidase (katG), the alkyl hydroperoxide reductase subunit C (ahpC), superoxide dismutase (SOD), hemeproteins, bacterial proteases, thioredoxin and lipoamide dehydrogenase (Lpd) can all scavenge ROS and RNS [33] . It has previously been shown that the loss of katG could render the bacteria susceptible to ROS and RNS, and a compensatory upregulation of the alkyl hydroperoxide (ahpC) gene could be the explanation for the increased resistance to NO [34, 35] . PBMC from MDRTB patients have been shown to produce large amounts of interleukin-10 [36] , which is known to reduce NO production and inhibit macrophage functions [37] [38] [39] .
Low levels of L-arginine which is important for NO production are found in patients with TB [40] . Clinical studies on the administration of intravenous or inhaled L-arginine have shown tumor reduction in breast cancer and improved pulmonary function in cystic fibrosis [41] . A diet with low L-arginine levels may impair NO synthesis and L-arginine supplementation is important for improving physical strength and to potentate sexual performance [42, 43] . Our previous study suggested supplementation of anti-TB chemotherapy with zinc and vitamin A [44, 45] ). There is also an association between human TB, protein-energy malnutrition, low BMI, and micronutrient malnutrition with low levels of substances such as vitamin A, vitamin D, iron, zinc, selenium, and plasma carotenoids [46] [47] [48] . In the preantibiotic era, cod liver oil [49] and phototherapy such as sun exposure of the skin [50] were include in the treatment of TB. Based on low NO levels in plasma and lysate of TB patients before chemotherapy, the present study therefore advocated arginine supplementation with anti-TB chemotherapy. Sputum levels of NO were higher in MDTB compared with DSTB and control. It is likely that sputum is a medium of transmission of M. tuberculosis and may contain higher concentrations of M. tuberculosis than blood. This proposition corroborates a previous study [39] that NO production is increased by NOS 2 mRNA expression and A549 lung epithelial cells which implicate the active involvement of lung epithelial cells in the anti-mycobacterial host defense process.
Throughout 6 months of treatment, the levels of NO in DSTB patients remained significantly unchanged. However, in MDRTB patients, the levels of NO increased with anti-TB treatment which might be due to a reduction in M. tuberculosis load or increased drug-induced NO production. Previous studies reported that M. tuberculosis clearance starts from 2 months posttreatment in some patients [44, 51, 52] . Reduced NO levels with treatment duration also supported previous reports that M. tuberculosis has scavenger functions against ROS and RNS in order to avoid decreased growth rate [53] [54] [55] . Therefore, the lesser the M. tuberculosis bacteria colonies, the higher the level of NO.
The study concluded that NO in the plasma, sputum, and mononuclear cell lysates are important in the defense against M. tuberculosis and that arginine supplementation is recommended with anti-TB therapy.
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